Discussion
The investigational therapy barzolvolimab rapidly reduced angioedema in people with chronic spontaneous urticaria (CSU) in a Phase 2 trial, and many remained free of swelling months after treatment ended. At the trial’s final assessment, conducted at week 76 (about 17.5 months after the study began), as many as 64%…